Bristol Myers Squibb
Cash engine facing a 2028 cliff
Bristol Myers Squibb is a scale biopharma with powerful intangible assets, top brands like Eliquis and Opdivo, and an expanding growth portfolio that includes Reblozyl, Breyanzi, Camzyos, Opdualag, Opdivo Qvantig and the newly approved schizophrenia therapy Cobenfy.
Recent results show the transition is working: Q2 2025 revenue was about 12.3 billion dollars with the growth portfolio up double digits, although legacy products continue to decline. Management reiterated a multi‑year productivity program and raised 2025 revenue guidance, but lowered adjusted EPS due to IPR&D and collaboration charges.
Financially, the company remains a cash machine. Using SEC filings, trailing twelve months through Q2 2025 operating cash flow is roughly 15.9 billion dollars and capex about 1.32 billion dollars, yielding approximately 14.6 billion dollars of free cash flow, or about 7.16 dollars per share on roughly 2.035 billion shares.
Net debt was about 35.2 billion dollars at June 30, 2025 and credit ratings are A2/A with stable outlooks. The U.S. 10‑year Treasury yield sits near 4.1 percent.
The core risk is the 2026 Medicare negotiated price for Eliquis and the U.S. generic entry permitted April 1, 2028, alongside Opdivo U.S. exclusivity expiring in 2028. BMS has moved to diversify via acquisitions of Karuna, RayzeBio and Mirati and by launching Opdivo Qvantig and Cobenfy, but execution must offset the cliff.
Our quality assessment acknowledges strong cash generation and scale moats, balanced against patent and pricing pressure and elevated acquisition risk.
Does Bristol Myers Squibb have a strong competitive moat?
BMS benefits from multiple moat sources: intangible assets (patents, regulatory exclusivities, brand and clinical data packages) across oncology, hematology, immunology, cardiovascular and neuroscience; scale in R&D, commercialization and manufacturing; and elements of efficient scale in complex modalities such as CAR‑T and radiopharmaceuticals.
Morningstar currently classifies BMY among its wide‑moat cohort, but we judge durability as narrower than the label implies due to approaching U.S. loss of exclusivity for Eliquis and Opdivo and IRA price pressures.
The 2024 Form 10‑K lists estimated minimum exclusivity dates: Eliquis U.S. 2028, Opdivo U.S. 2028, with footnotes noting EU pressure and actual early generic presence in some markets. Subcutaneous Opdivo Qvantig may defend share against biosimilar dynamics, but cannot eliminate the cliff.
Does Bristol Myers Squibb have pricing power in its industry?
Gross margin sits in the mid‑70s and non‑GAAP margin mix has been favorable, reflecting branded pricing power and portfolio mix. However, U.S. Medicare negotiated pricing begins in 2026 for Eliquis at a published 231 dollars 30‑day MFP, and U.S. generics may enter in 2028 under settlements, which will structurally erode pricing.
Oncology franchises retain some pricing power given clinical differentiation, and Opdivo Qvantig can preserve convenience and share. Net, we see solid but diminishing pricing power over the next 3 to 5 years.
How predictable is Bristol Myers Squibb's business?
The business has traditionally exhibited toll‑booth characteristics from chronic therapies, but the next three years are less predictable due to the IRA price reset and the 2028 LOE cluster. Q2 2025 showed resilience with revenue around 12.3 billion dollars and growth portfolio sales up strongly, and 2025 revenue guidance was raised.
Still, management flagged lower adjusted EPS on collaboration charges. We expect a trough around the 2026 to 2028 window followed by stabilization if launches (Cobenfy, Camzyos, Reblozyl expansions, Breyanzi growth, Krazati line extensions) execute.
Is Bristol Myers Squibb financially strong?
TTM free cash flow is approximately 14.6 billion dollars (CFO about 15.9 billion less capex about 1.32 billion). Cash, equivalents and marketable securities were about 14.0 billion dollars at June 30, 2025, and net debt about 35.2 billion dollars. Credit ratings are A2 at Moody’s and A at S&P with stable outlooks.
The dividend of 0.62 dollars per quarter continues and was reaffirmed in September 2025. Balance sheet strength and strong cash conversion should comfortably service maturities and fund R&D, though acquisition debt and IPR&D charges add variability.
How effective is Bristol Myers Squibb's capital allocation strategy?
BMS leaned into large acquisitions to backfill the cliff: Karuna (closed March 2024), RayzeBio (closed February 2024) and Mirati (closed January 2024). 2024 cash flows show over 21.8 billion dollars of acquisition and other payments; share repurchases paused in 2024 after 5.2 billion dollars in 2023. The strategy diversifies into neuroscience and radiopharma and adds Krazati in oncology, but raises integration and return‑on‑capital risks; 2024 GAAP results were heavily impacted by 13.4 billion dollars of acquired IPR&D expense.
We view capital allocation as mixed until new assets deliver durable cash returns.
Does Bristol Myers Squibb have high-quality management?
CEO Chris Boerner, formerly Chief Commercialization Officer and COO, became CEO in November 2023 and Board Chair in April 2024. His tenure has emphasized productivity and BD execution while advancing launches such as Cobenfy and Opdivo Qvantig.
Leadership has communicated a multiyear cost‑savings plan and a focus on growth in the back half of the decade, but the period will test portfolio execution amid LOEs.
Is Bristol Myers Squibb a quality company?
Bristol Myers Squibb is an average quality company with a quality score of 62/100
- Powerful cash generator with TTM FCF near 14.6 billion dollars and A‑level credit, supporting resilience through the transition.
- Clear 2026 to 2028 headwinds: Medicare MFP on Eliquis in 2026 and U.S. generics allowed in 2028; Opdivo U.S. exclusivity also 2028.
- New growth drivers are scaling: Opdivo Qvantig, Reblozyl, Breyanzi, Camzyos, Opdualag and Cobenfy; growth portfolio rose strongly in Q2 2025.
- Capital allocation skewed to large M&A (Karuna, RayzeBio, Mirati) increases execution risk but broadens neuroscience, radiopharma and targeted oncology.
- Fair value framework anchored on TTM FCF per share around 7.16 dollars and a conservative 10x multiple given the cliff, implying a prudent entry threshold.
What is the fair value of Bristol Myers Squibb stock?
Is Bristol Myers Squibb a good investment at $62?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.